A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

By Jie Yang, Leah R. Haworth, R. Sherry, P. Hwu, D. Schwartzentruber, S. Topalian, S. Steinberg, Helen X. Chen, S. Rosenberg. New England Journal of Medicine, 2003

2,835 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/b3c5ae396acc8dd24984d4cbb04aebc5c6b6c9f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. Hanahan
2. R. Weinberg
3. W. Kaelin
4. Andrew K. Joe
5. G. Bergers
6. D. Hicklin
7. O. Casanovas
8. I. Weinstein

In Pulmonary and Respiratory Medicine

1. R. Weinberg
2. B. Rini
3. D. Hanahan
4. P. Steeg

In Surgery

1. R. Weinberg
2. W. Kaelin
3. William Y. Kim
4. B. Rini
5. D. Hanahan
6. G. Semenza

Citations in the corpus

• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (2006, background): “and that bevacizumab, a monoclonal antibody to VEGF, might have significant antitumor activity in carcinomas of the breast, colon and kidney”
• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (2007, result): “prolonged the time to progression for patients with metastatic renal cell carcinoma compared with that for patients receiving placebo.(15) A preliminary report of the combination of bevacizumab and irinotecan for patients with malignant gliomas demonstrated an encouraging response rate of 43%.”
• Review: Hydrothermal technology for smart materials (2016, background): “Among the perovskite-type compounds, crystalline BST has received much attention due to attractive ferroelectric, pyroelectric and piezoelectric properties and high dielectric constants coupled with good thermal stability.(117) Partial substitution of network atoms by another isovalent cation (Ba, M”
• Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. (2008, result): “Importantly, the toxicity profile of bevacizumab in TREE-2 was consistent with other reports.(3-5,7,8) The incidence of grade 3/4 hypertension in TREE-2 (7% to 15% grade 3) was similar to that with bevacizumab 5 mg/kg in combination with FU/LV (9%) or IFL (11% grade 3) as first-line therapy for mCRC”
• Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth (2003, background): “In a recent Phase II study, a neutralizing VEGF antibody was shown to delay disease progression in metastatic renal carcinoma (Yang et al. 2003) and offers hope that rational combinations of small molecules directed against HIF targets will alter the natural history of this disease.”
• The tumor microenvironment. (2012, background): “This drug is currently used in treating metastatic colorectal cancer, glioblastoma, nonsmall cell lungcancer, and renal cell cancer [56,57].”
• Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “Bevacizumab, a recombinant humanized monoclonal antibody that binds VEGFA, has clinical activity in metastatic cancers in combination with cytotoxic agent”